ALBUQUERQUE, N.M., Oct. 25, 2012 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty focused molecular diagnostics laboratory that discovers, develops and markets proprietary tests for rheumatologists, announced today that it has received approval to offer its patent-protected Avise SLE diagnostic, SLE-Systemic Lupus Erythematosus, in New York. This certification means that the Avise SLE brand is now available to help lupus and connective tissue disease patients nationwide. Lupus is an autoimmune disease characterized by acute and chronic inflammation of various tissues of the body. Autoimmune diseases are illnesses that occur when the body’s tissues are attacked by its own immune system.
Avise SLE is a five-marker diagnostic blood test developed to help rule in lupus and rule out other rheumatic diseases. Exagen also offers its newest panel, Avise SLE+ Connective Tissue, which is a comprehensive connective tissue disease diagnostic specifically created to help provide assistance with differential diagnosis of autoimmune diseases. Benefits include:
- Avise SLE & Avise SLE+ Connective Tissue work together as a convenient 19-marker diagnostic to provide greater sensitivity and specificity over standard ANA and dsDNA.
- Incorporates the power of the biologically rational CB-CAPs technology to deliver a single test with more accurate ability to differentially diagnose SLE and other Connective Tissue Diseases.
- Provides more information to help determine definitive and earlier diagnosis, reduce chance of mis-diagnosis and alleviate patient anxiety.
“Exagen is pleased to be able to offer the Avise SLE diagnostic to physicians and patients in New York,” said Ron Rocca, CEO. “We strongly believe in providing access to all patients and this final certification allows for that and enables us to support physicians nationwide.”
About Exagen
Exagen Diagnostics, Inc. is a patient focused, discovery driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology. Committed to Personalized Medicine, our tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. For more information, please visit www.AviseTest.com.
SOURCE Exagen Diagnostics, Inc.
